Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The liver is a key player in glucose regulation, and several factors are involved in this regulation (1). Glucagon, au-tonomic nerves, and the adrenals stimulate hepatic glu-cose production to allow sufficient brain glucose delivery. Insulin inhibits hepatic glucose production, preventing excess hepatic glucose release. This is of particular impor-tance after meals, as is evident from the negative corre-lation between early insulin response after meals and postprandial glucose (2). Therefore, low insulin and high glucagon levels—such as observed in type 1 and type 2 diabetes—sustain liver glucose production, thereby result-ing in postprandial and fasting hyperglycemia. Thus, re-ducing hepatic glucose production is an important target in the treatment of diabetes (3). The incretin hormone GLP-1 inhibits hepatic glucose
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 reduces hepatic glucose production, partly by inhibiting the expression and activity of key gluconeogenic enzymes.189–191”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [189]
Citations
Cites
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 3×
“In fact, the first evidence of reduced glucagon levels by GLP-1 in type 1 diabetes was reported more than 20 years ago (17).”
BackgroundResultMitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595 · cited 1×
“This is of particular importance after meals, as is evident from the negative correlation between early insulin response after meals and postprandial glucose (2).”
BackgroundGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Hormonal regulation of hepatic glucose production in health and disease
Lin, H. V., & Accili, D. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.003 · Cited by 429 · cited 1×
“The liver is a key player in glucose regulation, and several factors are involved in this regulation (1).”
BackgroundGlucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 3×
“glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus.”
BackgroundResultVahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318 · cited 3×
“glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus.”
BackgroundResultKielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165
Direct effect of GLP-1 infusion on endogenous glucose production in humans
Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E. (2013) · Diabetologia · doi:10.1007/s00125-012-2738-3 · Cited by 143 · cited 1×
“glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus.”
BackgroundLARSSON, H., HOLST, J. J., & AHRÉN, B. (1997) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.1997.00161.x · Cited by 114 · cited 2×
“Proc Natl Acad Sci USA 2003;100:1438–1443 Figure 1—GLP-1 is released from the gut after meal ingestion and inhibits hepatic glucose release by the dual islet effects to stimulate insulin secretion and inhibit glucagon secretion (4) and neuroincretin mechanisms (19).”
BackgroundFarngren, J., Persson, M., Schweizer, A., Foley, J. E., & Ahrén, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2332 · Cited by 95 · cited 3×
“GLP-1 receptor agonists, liraglutide and exenatide (14,15), and the dipeptidyl peptidase-4 inhibitor vildagliptin (16) have demonstrated glucose-reducing effects in type 1 diabetes, which have been thought to be mainly due to inhibition of glucagon levels.”
BackgroundResult
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
Vagal mediation of GLP-1's effects on food intake and glycemia
Krieger, J.-P., Langhans, W., & Lee, S. J. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.001 · Cited by 67
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 33
“In the liver, it diminishes glucose production by blocking gluconeogenic enzymes, which are essential proteins in glucose synthesis (Ahrén 2015; Holter et al. 2022).”
Metadata
- Authors
- Ahrén, B.
- Affiliations
- Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-02-17
- Volume
- 64
- Issue
- 3
- Pages
- 715-717
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2159326211
- Cited by
- 13
- References
- 20
- Citations by year
- 2025: 2 · 2024: 3 · 2020: 1 · 2019: 1 · 2017: 2 · 2016: 1 · 2015: 3
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, hepatic glucose production, type 1 diabetes, incretins, glucagon, insulin, postprandial hyperglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Glucagon, Glucose, Insulin, Receptors, Glucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/db14-1671
- The paper
- Ahrén, B. (2015). Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes. Diabetes. https://doi.org/10.2337/db14-1671
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.